Rising Biosciences
Receives FDA Clearance for TSW
Pain Cream; Expedites Testing of
CBD Only
Variants of
Cannophen and TSW Pain
Cream Products
RBII Seeks Corporate
Registration in Canada Alongside Country's Decision to Legalize
Marijuana
Sandusky, Ohio -- October
10, 2018 -- InvestorsHub NewsWire -- Rising Biosciences, Inc.
(RBII)
("RBII" "the Company"), a research and development company focusing
on oral and topical pharmaceuticals with strict standards set
forward by the pharmaceutical compounding industry, is pleased to
announce that we have completed, and passed all testing
requirements for the FDA on its over-the-counter version of its TSW
Pain Cream, and the product is now moving into
production.
"The past 30 days have been
very exciting for our industry," states Rising Biosciences COO
Arthur Hall. " On September 21st, we completed our FDA testing on
TSW, and last week, the DEA moved to place certain FDA approved CBD
drugs down from Schedule I to Schedule V. It is the first time the
agency has lowered any type of cannabis from Schedule 1, indicating
the agency's recognition of Cannabidiol as a viable medical
treatment. Rising
Biosciences is looking forward to working
with the Canadian testing company ABICH Inc., who completed the FDA
testing on our over-the-counter version of TSW Pain Cream for our
testing needs on the CBD only variants of Cannophen and TSW Pain
Cream."
As well, on
October
17th, 2018, Marijuana becomes
legal in Canada as a result of 'The Cannabis Act', passed on June
3rd, 2018, marking Canada as the
first G7 country to legalize Marijuana. Rising Biosciences has
decided to seek registration as a foreign corporation in
Canada to
assertively expand operations there in wake of
legalization.
"This is a special time for
the Company and its Shareholders," states Hall. "We have taken the
company from dedicated vision to a fully integrated R&D,
manufacturing and distribution, and are now ready for
market. We are grateful for shareholder patience, and support
through the monumental steps we've taken over the past year and a
half, and we are now taking the Company to new heights with some
major updates to follow."
$RBII on Twitter for LIVE
company updates! www.twitter.com/risingindiausa
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act
of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934,
and are subject to the safe harbor created by those rules. All
statements, other than statements of fact, included in this
release, including, without limitation, statements regarding
potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward- looking statements to reflect events or circumstances
after the date of this release.
CONTACT INFO: For
Investor Inquiries: IR@risingbiosciences.com
